The different pattern of blood S100B protein and GFAP concentrations in ischemic stroke
DOI:
https://doi.org/10.13181/mji.v22i4.602Keywords:
GFAP, ischemic stroke, NIHSS, S100B proteinAbstract
Background: S100B protein and glial fibrillary acidic protein (GFAP) released during ischemia have been associated with stroke. This study aimed to know whether there was a correlation between the concentration of these markers with the severity of neurological deficit in ischemic stroke.
Methods: This was a cross-sectional study, which involved 143 ischemic stroke patients who were admitted to hospital not more than 72 hours after the onset and fulfilled the criteria. The concentration of S100B protein and GFAP was determined by ELISA method. Blood level of S100B and GFAP in patient with mild, moderate, and severe stroke were analyzed with Kruskal-Wallis test.
Results: There was a significant difference between S100B protein concentration among subjects with mild (median 63.31 ng/L), moderate (median 88.93 ng/L), and severe (median 511.55 ng/L) NIHSS at admission (p < 0.05). A weak significant correlation was found between the severity of NIHSS and the S100B protein concentration. The more severe the NIHSS, the higher the S100B protein concentration (r = 0.351; p < 0.001). Subjects with moderate and severe NIHSS were more frequent to have an intermediate or high level of S100B protein than the subjects with mild NIHSS (OR = 3.9; p < 0.001). The median concentration of GFAP was significantly higher in severe NIHSS subjects (median 0.374 ng/mL) than its concentration in mild (median 0.047 ng/mL) and moderate (median 0.043 ng/mL) NIHSS subjects (p < 0.05).
Conclusion: S100B protein concentration was significantly higher in linier relation with the severity of NIHSS, while the GFAP concentration was significantly higher if the NIHSS had been already severe. (Med J Indones. 2013;22:215-20. doi: 10.13181/mji.v22i4.602)
Keywords: GFAP, ischemic stroke, NIHSS, S100B protein
Downloads
References
Lynch JR, Blessing R, White WD, Grocott HP, Newman MF, Laskowitz DT. Novel diagnostic test for acute stroke. Stroke. 2004;35(1):57-63. http://dx.doi.org/10.1161/01.STR.0000105927.62344.4C
Whiteley W, Tseng MC, Sandercock P. Blood biomarker in the diagnosis of ischemic troke: A systematic review. Stroke. 2008;39:2902-9. http://dx.doi.org/10.1161/STROKEAHA.107.511261
Endres M, Dirnagil U, Moskowitz MA. The ischemic cascade and mediators of ischemic injury. 2009. In: Fisher M, editor. Handbook of clinical neurology, vol 92 (3rd series) Stroke. Part I. Boston: Elsevier; 2009. p. 31-41.
Graham SH, Hickey RW. Molecular pathophysiology of stroke. In: Davis KL, Charney D, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology: the fifth generation of progress. Pennsylvania: American College of Neuropsychopharmacology. 2002. p. 1317-26.
Lakhan EL, Kirchgessner A, Hofer M. Inflammatory mechanisms in ischemic stroke: theraupetic approaches. J Transl Med. 2009;7:97-107. http://dx.doi.org/10.1186/1479-5876-7-97
Saenger AK, Christenson RH. Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation, and treatment. Clin Chem. 2010;56(1):21-33. http://dx.doi.org/10.1373/clinchem.2009.133801
Hill MD. Diagnostic biomarkers for stroke: a stroke neurologist's perspective. Clin Chem. 2005;51(11):2001-2. http://dx.doi.org/10.1373/clinchem.2005.056382
Jauch ECJ. Biomarker advances in acute ischemic stroke. In: Advancing the Standard of Care: Cardiovascular and Neurovascular Emergencies. Division of Emergency Medicine, Washington University School of Medicine, Cincinnati; 2005
Jickling G, Xu H, Sharp F. Biomarkers of ischemic stroke. US Neurology. 2009;5:52-4.
Liswaty E, Wijaya A, Ranakusuma TAS. Biochemical markers for differential diagnosis of stroke: a biochemical marker study of S100B protein, neuron specific enolase (NSE), myelin basic protein (MBP), and heart-type fatty acid binding protein (H-FABP). Indonesian Biomedical Journal. 2009;1:68-72.
Buttner T, Weyers S, Postert T, Sprengelmeyer R, Kuhn W. S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction. Stroke. 1997;28(10):1961-5.
http://dx.doi.org/10.1161/01.STR.28.10.1961
Missler U, Wiesmann M, Wittmann G, Magerkurth O, Hagenstrom H. Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results. Clin Chem. 1999;45(1):138-41.
Wunderlich, MT, Ebert AD, Kratz T, Goertler M, Jost S, Herrmann M. Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke. 1999;30(6):1190-5. http://dx.doi.org/10.1161/01.STR.30.6.1190
Herrmann M, Vos P, Wunderlich MT, de Bruijn CHMM, Lamers KJB. Release of glial tissue-specific proteins after acute stroke: a comparative analysis of serum concentration of protein S-100B and glial fibrillary acidic protein. Stroke. 2000;31(11):2670-7. http://dx.doi.org/10.1161/01.STR.31.11.2670
Ali MS, Harmer M, Vaughan R. Serum S100 protein as a marker of cerebral damage during cardiac surgery. Br J Anaesth. 2000;85(2):287-98. http://dx.doi.org/10.1093/bja/85.2.287
Michetti F, Gazzolo D. S100B Protein in biological fluids: a tool for perinatal medicine. Clin Chem. 2002;48(12):2097-104.
Yu ACH, Wong HK, Yung HW, Lau LT. Ischemia â?? induced apoptosis in primary cultures of astrocytes. Glia. 2001;35(2):121-30. http://dx.doi.org/10.1002/glia.1077
Sofroniew MV, Vinters HV. Astrocytes: Biology and pathology. Acta Neuropathol. 2010;119(1):7-35. http://dx.doi.org/10.1007/s00401-009-0619-8
Foerch C, Curdt I, Yan B, et al. Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J. Neurol. Neurosurg. Psychiatry. 2006;77(2):181-4. http://dx.doi.org/10.1136/jnnp.2005.074823
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.
